


The fund's investment objective is to achieve income with the potential for some capital growth from a portfolio made up mainly of the securities of UK companies.
| Name | % Net Assets | 
|---|---|
| BG Group PLC | 6.6% | 
| AstraZeneca PLC | 6.5% | 
| GlaxoSmithKline PLC | 6.1% | 
| Vodafone Group PLC | 6.0% | 
| Imperial Tobacco Group PLC | 5.2% | 
| British American Tobacco PLC | 4.7% | 
| Royal Dutch Shell PLC | 4.1% | 
| Centrica PLC | 4.0% | 
| Roche Holding AGCFD | 3.5% | 
| BT Group PLC | 3.4% | 
| Key | % Net Assets | 
|---|---|
| 6.6% | |
| 6.5% | |
| 6.1% | |
| 6.0% | |
| 74.8% | 
| Date | 20-Aug-2025 | 
|---|---|
| NAV | 88.15p | 
| Currency | GBP | 
| Change | 0.41p | 
| % | 0.47% | 
| YTD change | 3.49p | 
| YTD % | 4.12% | 
| Fund Inception | 02/02/2009 | 
|---|---|
| Fund Manager | n/a | 
| TER | 1.75 (28-Feb-2012) | 
| Minimum Investment | |
|---|---|
| Initial | n/a | 
| Additional | n/a | 
| Savings | n/a | 
| Charges | |
|---|---|
| Initial | 3.50% | 
| Annual Mang't | 1.50% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| No risk data available. | |
You are here: research